13 institutions hold shares in ASLAN Pharmaceuticals Limited (ASLN), with institutional investors hold 11.39% of the company’s shares. The shares outstanding are 37.99M, and float is at 1.75M with Short Float at 68.58%. Institutions hold 11.39% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Ikarian Capital, LLC with over 2.01 million shares valued at $3.67 million. The investor’s holdings represent 5.28% of the ASLN Shares outstanding. As of Dec 30, 2020, the second largest holder is Temasek Holdings (Private) Limited with 1.68 million shares valued at $3.07 million to account for 4.42% of the shares outstanding. The other top investors are Sio Capital Management, LLC which holds 1.39 million shares representing 3.67% and valued at over $2.55 million, while Platinum Investment Management Ltd holds 1.36% of the shares totaling 0.51 million with a market value of $0.94 million.
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) is 86.89% higher on its value in year-to-date trading and has touched a low of $0.95 and a high of $6.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ASLN stock was last observed hovering at around $3.57 in the last trading session, with the day’s loss setting it -0.15% off its average median price target of $8.50 for the next 12 months. It is also 62.0% off the consensus price target high of $9.00 offered by 3 analysts, but current levels are 57.25% higher than the price target low of $8.00 for the same period.
Currently trading at $3.42, the stock is -8.64% and -2.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.69 million and changing -4.20% at the moment leaves the stock 53.84% off its SMA200. ASLN registered 232.04% gain for a year compared to 6-month gain of 77.20%. The firm has a 50-day simple moving average (SMA 50) of $3.8203 and a 200-day simple moving average (SMA200) of $2.4443.
The stock witnessed a 2.09% loss in the last 1 month and extending the period to 3 months gives it a 71.86%, and is 5.23% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.34% over the week and 9.81% over the month.
Distance from 52-week low is 260.00% and -49.33% from its 52-week high. The company has generated returns on investments over the last 12 months (-283.40%).
ASLAN Pharmaceuticals Limited (ASLN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ASLAN Pharmaceuticals Limited (ASLN) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 2.30, where 1 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ASLAN Pharmaceuticals Limited is expected to release its quarterly report on 08/09/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to shrink by -5.20% this year